Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability study of TAK-861 in narcolepsy type 1
NL-OMON59722Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oveporexton in narcolepsy type 1 (NT1), sponsored by Takeda. Primary endpoint: Occurrence of at least 1 treatment-emergent adverse event. Started May 2023; status: recruiting.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON59722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59722.